Enveric Biosciences (NASDAQ:ENVB) Releases Earnings Results

Enveric Biosciences (NASDAQ:ENVB) released its quarterly earnings results on Friday. The company reported ($1.08) earnings per share for the quarter, FiscalAI reports.

Enveric Biosciences Price Performance

Enveric Biosciences stock traded down $0.04 during mid-day trading on Friday, reaching $2.25. The company had a trading volume of 134,720 shares, compared to its average volume of 11,244,770. Enveric Biosciences has a 1 year low of $1.71 and a 1 year high of $17.64. The company has a market capitalization of $4.48 million, a P/E ratio of -0.06 and a beta of 1.24. The stock’s 50-day simple moving average is $2.55 and its 200-day simple moving average is $3.79.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Enveric Biosciences stock. AdvisorShares Investments LLC lifted its holdings in shares of Enveric Biosciences, Inc. (NASDAQ:ENVB) by 96.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 203,679 shares of the company’s stock after purchasing an additional 100,000 shares during the period. AdvisorShares Investments LLC owned about 39.32% of Enveric Biosciences worth $130,000 as of its most recent SEC filing. 13.82% of the stock is currently owned by institutional investors.

Enveric Biosciences Company Profile

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.